Impact of SC Daratumumab

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Panelists discuss how the FDA approval of daratumumab and hyaluronidase-fihj combined with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible newly diagnosed multiple myeloma patients is changing treatment approaches while also considering how recent evidence suggesting reduced observation time for subcutaneous (SC) daratumumab administration may streamline patient care and improve treatment efficiency.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

EP: 6.Key End Points in Clinical Trials

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

Now Viewing

EP: 10.Impact of SC Daratumumab

Video content above is prompted by the following:

With the new FDA approval of daratumumab and hyaluronidase-fihj in combination with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma, how does this impact treatment within this patient population?
(Dr Adams) A recent pharmacy-led initiative showed that observation following subcutaneous administration of daratumumab may not be needed if the first injection is tolerated. How does this change patient monitoring procedures by the care team?